Transoral robotic surgery with neck dissection versus nonsurgical treatment in stage I and II human papillomavirus-negative oropharyngeal cancer

Head Neck. 2022 Jul;44(7):1545-1553. doi: 10.1002/hed.27045. Epub 2022 Apr 1.

Abstract

Background: Surgery + adjuvant therapy was shown to have improved overall survival (OS) versus nonsurgical treatment in T1-T2N1-N2b human papillomavirus (HPV)-negative oropharyngeal cancer (OPC). Our objective was to compare OS in transoral robotic surgery (TORS) with neck dissection versus nonsurgical treatment for T1-T2N0 HPV-negative OPC.

Methods: Patients with T1-T2N0 HPV-negative OPC were identified in the National Cancer Database. OS was compared between groups: (1) TORS with neck dissection +/- adjuvant therapy, (2) primary radiotherapy (>60 Gy) +/- chemotherapy using Kaplan-Meier and multivariable Cox proportional hazards models.

Results: There were 665 (78.4%) patients treated nonsurgically and 183 (21.6%) patients in the TORS group. Adjusting for age, comorbidity score, facility type, tumor subsite, and tumor stage, primary nonsurgical treatment was associated with worse OS (hazard ratio: 1.90, 95% CI: 1.34-2.69).

Conclusion: For T1-T2N0 HPV-negative OPC, TORS with neck dissection may be associated with a survival benefit over nonsurgical treatment.

Keywords: human papillomavirus-negative; minimally invasive surgery; oropharyngeal cancer; radiation therapy; transoral robotic surgery.

MeSH terms

  • Alphapapillomavirus*
  • Humans
  • Neck Dissection
  • Oropharyngeal Neoplasms* / pathology
  • Oropharyngeal Neoplasms* / surgery
  • Papillomavirus Infections* / pathology
  • Retrospective Studies
  • Robotic Surgical Procedures*